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Summary
Objectives: Thyroid hormones induce features of the hypertrophic phenotype in mature articular chondrocytes as well as in growth plate
chondrocytes. Hypertrophic chondrocytes are responsible for extracellular matrix mineralization, with formation of bone mineral in growth
plate cartilage and pathologic calcium crystals in aging articular cartilage. Elevated activity levels of the two transglutaminase (Tgase)
enzymes (type II Tgase and Factor XIIIA (FXIIIA)) have recently been described as additional features of hypertrophic growth plate
chondrocytes. Because Tgases may participate in pathologic mineralization in aging cartilage, we explored the effects of thyroid hormones
on Tgase activity in articular chondrocytes.
Methods: Adult porcine articular chondrocytes were incubated with or without 250–750 nM L-thyroxine (T4) or 10–100 nM 3,3′,5-tri-
iodothyronine (T3). Tgase activity was measured with a standard radiometric assay. The effects of thyroid hormones on protein and mRNA
levels of type II Tgase and FXIIIA were determined. As Tgase activity can be stimulated by proteases, endoproteinase levels were also
measured. The mechanisms of these effects were explored.
Results: T4 (750 nM) or T3 (100 nM) stimulated Tgase activity by twofold in articular chondrocytes at 4 h and increased the percentage of
Tgase activity in the extracellular matrix. Chondrocytes rapidly converted T4 to T3, but the time course suggests similar mechanisms for T4
and T3. T4-induced Tgase activity was suppressed with cycloheximide and protein kinase C inhibitors. The effects of T4 on type II Tgase and
FXIIIA levels were modest, but T4 strongly induced endoproteinase activity in chondrocytes.
Conclusions: We report in this study that thyroid hormones increase Tgase activity in articular chondrocytes via a non-genomic mechanism,
which may involve increased endoproteinase secretion.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
The transglutaminase (Tgase) enzyme family comprises at
least nine different enzymes that form ε-(γ-glutamyl) lysine
bonds between or within proteins1. Recent evidence sup-
ports the hypothesis that Tgases participate in the patho-
logic cartilage matrix mineralization that often accompanies
degenerative arthritis, and that results in apatite and cal-
cium pyrophosphate dihydrate (CPPD) crystal formation2.
Tgase activity levels dramatically increase with age in
articular chondrocytes, mirroring the increased preva-
lence of clinical degenerative arthritis and articular calcium
crystal deposition3. Increased Tgase activity correlates with
elevated protein levels of the two forms of Tgase present in
articular cartilage: Factor XIIIA (FXIIIA) and type II
Tgase3,4. Tgase enzymes are present in the pericellular
matrix of osteoarthritic chondrocytes at potential sites of
pathologic calcium crystal formation5. In vitro, Tgase en-
zymes participate in the formation of apatite crystals in
cartilage2, while Tgase inhibitors suppress CPPD crystal
formation6.
Little is known about the regulation of Tgase activity in
articular cartilage. Interleukin 1 remains the only identified
stimulant of chondrocyte Tgase activity2. However, pro-
teases, including trypsin and thrombin, are potent stimu-
lants of Tgase action in other settings7,8. These enzymes
can directly activate FXIIIA through proteolytic cleavage
of an activation peptide8, and can upregulate enzyme
synthesis7.
Although little is known about the causes of pathologic
mineralization in degenerative arthritis, there is ample evi-
dence to suggest that the chondrocytes responsible for this
activity have many features in common with the hyper-
trophic chondrocytes that mineralize extracellular matrix in
growth plate cartilage. Histologic studies show abnormally
large chondrocytes near CPPD crystal deposits9. Aging
articular chondrocytes and hypertrophic chondrocytes both
elaborate matrix vesicles, which may directly participate in
mineralization10,11. Thyroid hormones induce markers of
the hypertrophic phenotype, such as type X collagen, and
alkaline phosphatase, in both growth plate12 and aging
articular chondrocytes13, and are capable of inducing
matrix mineralization in cultured chondrocytes under
serum-free conditions12.
Recently, elevated levels of Tgase proteins have been
described as an additional feature of the hypertrophic
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phenotype of growth plate chondrocytes14,15. These en-
zymes likely alter extracellular matrix proteins so as to
facilitate mineral deposition16. In this study, we sought to
determine if thyroid hormones increase Tgase activity in
articular chondrocytes, and to explore the mechanism
of this effect. We show in this study that L-thyroxine (T4)
and 3,3′ 5-triiodothyronine (T3) markedly stimulate Tgase
activity in articular chondrocytes. The mechanism is likely
non-genomic, is protein kinase C-dependent and involves
increases in endoproteinase activity.
Materials and methods
CHONDROCYTE CULTURES
Normal porcine articular cartilage was removed from the
femoral and patellar surfaces of 3–5 years old animals
(Johnsonville Foods Company, Watertown, WI). Chondro-
cytes were enzymatically isolated as previously described
and plated at 4×105 cells/cm2 in Dulbecco’s Modified
Eagle’s Medium (DMEM; Mediatech, Herndon, VA) with
10% fetal calf serum13. Within 2–3 days of plating, the
culture medium was changed to DMEM with 0.35 mg/ml
bovine serum albumin (BSA) for 24 h. Experiments were
performed in serum-free DMEM with 0.35 mg/ml BSA and
10–100 nM T3 or 250–750 nM T4 (Sigma Chemical Co.,
St. Louis, MO). These concentrations had previously been
shown to be effective in stimulating markers of hypertrophy
in articular chondrocytes13. For some experiments, whole
cell layers were obtained by scraping chondrocytes and
matrix off culture plates. Extracellular matrix was isolated
from parallel cultures using sodium deoxycholate17. In
other experiments, cell lysates were obtained by exposure
of chondrocytes to M-PER™ (Pierce, Rockford, IL). Cytosol
and membrane fractions were isolated by centrifuging cell
lysates for 5 min at 6000×g to remove debris, and then for
30 min at 48 000×g4.
INHIBITORS
The non-glycosidic indolocarbazole (NGIC; 10 nM; Cal-
biochem) was used to block protein kinase C activity.
Actinomycin D (100 nM; Sigma Chemical Co.) and cyclo-
heximide (500 nM; Sigma Chemical Co.) were used to
inhibit mRNA production and protein synthesis, respec-
tively. α1 antitrypsin (50 µg/ml; ICN, Costa Mesa, CA) was
used as an endoproteinase inhibitor.
TGASE ASSAY
A standard radiometric assay based on the ability of
Tgase to incorporate (3H)putrescine into casein was used
to measure Tgase activity in cell layers, cell fractions and
extracellular matrix3. Results were expressed as Units
(picomoles casein incorporated per 30 min) corrected for
the protein content of the sample.
T3 ASSAY
Chondrocytes were incubated with no additives or
3 ng/ml T3 or 10 ng/ml T4 for 4 h. T3 levels were measured
in the cell layer using a commercial enzyme immunoassay
(EIA) test kit for T3 according to manufacturer’s directions
(ICN Pharmaceuticals, Orangeburg, NY).
WESTERN BLOTTING
Chondrocytes were lysed with M-PER™ after incubation
for 4 h with or without thyroid hormones. Volumes of cell
lysate normalized for protein content were loaded onto 10%
NuPage® Bis-Tris gels (Invitrogen, Carlsbad, CA). Proteins
were transferred to poly(vinylidene) difluoride (PVDF)
membranes. After blocking for 1 h in Tris-buffered saline-
Nonidet P40-5% skim milk, they were incubated with 1:250
dilution of goat anti-type II Tgase (Upstate Biotechnology,
Lake Placid, NY) or 1:1000 dilution of rabbit anti-FXIII-A
subunit (Calbiochem). There is no cross-reactivity between
these antibodies, although both forms of Tgase are of
similar molecular weight in chondrocytes4. The appropriate
Immunopure® peroxidase-conjugated secondary antibody
was used. The blot was developed with Supersignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
For protein kinase C translocation experiments, chondro-
cytes were fractionated into cytosolic and membrane com-
partments4, and blotted with a 1:500 dilution of rabbit
anti-protein kinase C αβγ (Life Technologies, Gaithersburg,
MD).
FXIIIA ELISA
This assay accurately measures total FXIIIA protein
levels and is based on a protocol from Affinity Biologicals
(Ontario, Canada). Costar high-binding plates were coated
with a 1:100 dilution of rabbit anticoagulation FXIIIA-
subunit (100 µl/well; Calbiochem) in coating buffer (50 mM
carbonate–bicarbonate, pH 9.6) overnight at 4°C. The
plates were blocked with 1% BSA in PBS (130 mM NaCl,
4 mM Na2HPO4, 1.5 mM KH2PO4, 2.8 mM KCl, pH 7.4) for
60 min at room temperature. After washing with PBS–
Tween (PBS with 1% Tween-20), 100 µl of cell lysate was
added to the wells. The plates were incubated overnight at
room temperature, and washed again in PBS–Tween.
Detecting antibody (100 µl), peroxidase-labeled sheep anti-
Human FXIIIA (Affinity Biologicals), diluted 1:500 (25 mM
Hepes free acid, 25 mM NaCl, 1% BSA, 0.1% Tween-20,
pH 7.2), was added to the wells and incubated at
room temperature for 60 min. After washing, 100 µl
O-phenylenediamine substrate (OPD, 10 mg in 24 ml in
13.5 mM citric acid, 25 mM Na2HPO4, pH 5.0) was added
for 5–10 min until the color developed. The reaction was
stopped with 2.5 M H2SO4. The plates were read in a
BioTek ELx-800 microplate reader at 490 nm. A standard
curve was generated using recombinant human FXIII
protein (Neomarkers, Fremont, CA).
RT-PCR
Total RNA from chondrocytes was isolated by the acidi-
fied guanidinium isothiocyanate method, using TRIzol (Life
Technologies, Grand Island, NY). RNA was reverse-
transcribed as previously described and the generated
cDNA was amplified in a GeneAmp PCR System 2400™
thermocycler (Perkin–Elmer Biosystems, Foster City, CA)
using a PLATINUM™ PCR SUPERMIX (Life Technolo-
gies). Published primer sequences for human types I and II
deiodinases18,19, FXIIIA20 and type II Tgase21 were used.
Primer concentrations were 10 pm/µl. Reactions were run
for 40 cycles at 56°C. Transcripts were analyzed in 1.6%
agarose/TAE gel electrophoresis and visualized by SYBER
GREEN-I (Sigma Chemical Co.) using the Alpha Imager™
2000 system (AlphaInotech Co., San Leandro, CA).
464 A. K. Rosenthal et al.: Thyroxine and transglutaminase activity
CYCLIC AMP ASSAY
Cyclic AMP (cAMP) levels were determined with a com-
mercially available EIA kit used according to manufac-
turer’s directions (Assay Designs, Inc., Ann Arbor, MI).
Forskolin (7-deacetyl-7-[O-(N-methylpiperazino)-γ-butyryl]
dihydrochloride, 25 µM; Calbiochem) and IBMX (3-isobutyl-
1-methylxanthine, 25 µM; Calbiochem) served as positive
controls to raise intracellular cAMP levels.
ENDOPROTEINASE ASSAY
Chondrocytes were incubated with no additives or thy-
roid hormones for 4 h. Endoproteinase levels in media and
cell lysate were measured with a SpecWorks™ Protease
Assay Kit (Novagen, Madison, WI) according to manu-
facturer’s directions. This kit measures activity of endo-
proteinases including trypsin, elastase, proteinase K,
chymotrypsin, bromelain, thermolysin, pronase and papain.
TOXICITY ASSAY
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay was used to assess the toxicity of
culture additives17.
STATISTICAL ANALYSES
All experiments were repeated at least three times. A
Student’s t-test was used to determine statistically signifi-
cant differences between groups. A P value less than 0.05
was considered statistically significant.
3. Results
EFFECT OF THYROID HORMONES ON CHONDROCYTE TGASE
ACTIVITY
As shown in Fig. 1, T3 and T4 each stimulate Tgase
activity in a dose-dependent manner (P<0.01). Tgase
activity levels increased from control values of
0.19±0.02 U/mg protein to 0.40±0.03 U/mg protein with
750 nM T4, and from 0.11±0.02 to 0.27±0.01 U/mg protein
with 100 nM T3. Effects were maximal at 4 h of incubation,
but were present as early as 1 h (Table I).
T4 produced a shift of Tgase activity from cell to matrix
(Table II). Cell-associated Tgase activity was reduced from
39.1 to 19.4% with a concurrent increase in matrix-
associated Tgase activity from 60.8% in control cell layers
to 80.5% in T4-treated cell layers (P<0.01).
COMPARISON OF T4- AND T3-INDUCED TGASE ACTIVITIES
Most cells possess thyroid deiodinases, which convert
T4, the circulating form of thyroid hormone, to T3, the active
ligand for thyroid nuclear receptors. As shown in Fig. 2,
articular chondrocytes are capable of converting T4 to T3 at
4 h. Type II deiodinase was readily detected in articular
chondrocytes by RT-PCR (Fig. 3), while no signal for type I
deiodinase could be discerned (data not shown). When
cellular effects require conversion of T4 to T3, a time lag in
the effect of T4 compared with T3 is often seen. As shown
in Table I, the time courses of effects of T4 and T3 on
chondrocyte Tgase activity were similar. Taken along with
the rapid onset of action of T4 and T3, these data suggest
a non-genomic mechanism for thyroid hormone action.
EFFECT OF PROTEIN AND mRNA SYNTHESIS INHIBITORS ON
T4-INDUCED TGASE ACTIVITY
To further investigate whether protein or mRNA synthesis
was involved in this effect, we explored the actions of
actinomycin and cycloheximide on the ability of T4 to
induce Tgase activity. Actinomycin D had no effect on the
ability of T4 to increase Tgase activity, suggesting that
new mRNA synthesis was not necessary for this effect
(Fig. 4). Actinomycin had a modest stimulatory effect on
Tgase activity when used alone (P<0.01), suggesting that
Fig. 1. The effect of T3 and T4 on chondrocyte Tgase activity.
Chondrocytes were incubated for 4 h with no additives (control) or
with 250–750 nM T4 (A) or 25–100 nM T3 (B). Tgase activity was
measured in the whole cell layer and corrected for protein levels in
the sample. Results are expressed as means±standard errors of
the mean (N6). *Reflects statistically significant differences from
control values. T4 significantly increased Tgase activity at 500 nM
(P<0.02) and 750 nM (P<0.001), while T3 increased Tgase activity
at 50 nM (P<0.008) and 100 nM (P<0.007).
Table I
Time course of effect of T3 and T4 on Tgase activity
Time Tgase activity (% of control)*
T3 T4
15 min 129±7 112±4
30 min 131±9 108±8
1 h 174±10 170±14
2 h 116±7 116±6
4 h 140±20 255±30
24 h 100±6 150±9
*Chondrocytes were incubated for various lengths of time with
no additives (control), 100 nM T3 or 750 nM T4. Tgase activity was
measured in the cell layer and expressed as a percent of control
values. Values are means±standard deviations (N5).
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inhibition of mRNA production increased Tgase activity.
Further evaluation of this effect is ongoing. The RT-PCR
data confirmed only minimal changes in mRNA levels
for the Tgase enzymes with thyroid hormone treatment.
mRNA levels for type II Tgase were slightly decreased by
T4 or T3 [Fig. 5(A)], while mRNA levels for FXIIIA were
slightly increased by T3 or T4 [Fig. 5(B)]. In contrast,
cycloheximide inhibited the effect of T4 on Tgase activity
and had no effect when present alone (Fig. 4). Tgase levels
fell from 0.40±0.03 U/mg protein in T4-treated cell layers to
0.14±0.02 U/mg protein in cell layers treated with T4 and
cycloheximide (P<0.001). Moderate increases in type II
Tgase protein levels in T4-treated cultures were noted on
Western blots (Fig. 6). FXIIIA levels as measured by
Western blotting and ELISA were also modestly increased
by T4 (Figs. 7 and 8). Similar results were seen with T3
(data not shown). Neither inhibitor was toxic. These data
suggest that protein synthesis is necessary for thyroid
hormone to stimulate Tgase activity.
ROLE OF PROTEIN KINASE C OR cAMP IN THE EFFECT OF T4 ON
CHONDROCYTE TGASE ACTIVITY
Protein kinase C and cAMP mediate some of the non-
genomic effects of thyroid hormones in other settings22,23.
The protein kinase C inhibitor, NGIC, suppressed the ability
of T4 to stimulate Tgase activity (P<0.01), suggesting that
activation of protein kinase C may be involved in this effect
(Fig. 9). NGIC caused a modest increase in Tgase activity
for unclear reasons (P<0.04), and was non-toxic. The
protein kinase C dependence of this effect was confirmed
by demonstrating translocation of protein kinase C activity
from the cytosol to the membrane fraction of chondrocytes
treated with T4 (data not shown). As shown in Fig. 10,
levels of cAMP did not change in the presence of T4,
although they were dramatically increased with exposure to
the known cAMP stimulants forskolin and IBMX. There did
not appear to be any correlation between cAMP levels and
Tgase activity, as T4 was still capable of significantly
increasing Tgase activity even in the presence of high
cAMP levels.
Table II
The effect of T4 on the percentage of Tgase activity in various cell
compartments
Tgase activity (% total)*
Cell-associated Matrix
Control 39.1±5.6 60.1±5.6
T4 19.4±2.9 80.5±2.9
*Chondrocytes were incubated with or without 750 nM T4.
Tgase activity was measured in the cell-associated and extra-
cellular matrix compartments, and the percentage of activity in
each compartment was calculated. Results are expressed as
means±standard deviations (N3). Tgase activity is higher in the
matrix of T4-treated chondrocytes than in controls (P<0.01).
Fig. 2. The conversion of T4 to T3. Chondrocytes were incubated
with no additives (control), 10 ng/ml T4 or 3 ng/ml T3 for 4 h.
Levels of T3 were measured in the whole cell layer with a EIA kit.
Results are expressed as means±standard errors of the mean
(N10).
Fig. 3. RT-PCR of the type II deiodinase in chondrocytes. Total
RNA was extracted from chondrocytes incubated with no additives
(control), or 100 nM T3 or 750 nM T4 for 4 h. RT-PCR was
performed using a primer sequence that recognizes human type II
deiodinase. The arrow identifies a band corresponding to the
expected molecular weight of the type II deiodinase sequence.
Fig. 4. The effect of protein and mRNA inhibitors on the ability of T4
to stimulate Tgase activity. Chondrocytes were incubated with no
additives (control), 100 nM actinomycin (act), 500 nM cyclo-
heximide (cyclo), or 750 nM T4 with or without 100 nM actinomycin
or 500 nM cycloheximide for 4 h. Tgase activity was measured in
the whole cell layer and corrected for protein levels in the sample.
Results are expressed as means±standard errors of the
mean (N6). Actinomycin alone modestly increased Tgase activity
(P<0.01). Cycloheximide suppressed T4-induced Tgase activity
(P<0.001), while actinomycin had no effect on T4-induced Tgase
activity (P>0.01).
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EFFECT OF T4 ON ENDOPROTEINASE ACTIVITY
Certain proteases, such as trypsin and thrombin, stimu-
late Tgase activity through a variety of mechanisms24,
including direct proteolytic activation of FXIIIA25. As the
effects of thyroid hormones on Tgase enzyme protein
levels were so modest and did not correlate with the rapid
effects on activity, we asked if T4 might affect Tgase activity
by increasing endogenous proteinase activity. Using a kit
that detects activity of trypsin and other endoproteinases,
we demonstrated a significant increase in endoproteinase
activity in the cell layer and media of T4-treated chondro-
cytes compared with control values (Table III). Endo-
proteinase activity levels were undetectable in untreated
cell layers and media, and were 96±3 ng in the cell layer
and 239±13 ng in the media of T4-treated chondrocytes. To
further implicate endoproteinase secretion as a participant
in the effect of T4 on Tgase activity, we examined the
effects of the broad-spectrum endoproteinase inhibitor, α1
antitrypsin, on the ability of T4 to stimulate Tgase activity.
The α1 antitrypsin (50 µg/ml) caused a significant decrease
in T4-induced Tgase activity (P<0.02), while it had no effect
on Tgase activity when present alone (Fig. 11). These data
confirm a role for endoproteinase secretion in thyroid
hormone-mediated Tgase stimulation.
Discussion
We report in this study that thyroid hormones increase
Tgase activity in adult porcine articular chondrocytes. Simi-
lar concentrations of thyroid hormones stimulate other
markers of the hypertrophic phenotype in articular chondro-
cytes, including type X collagen production, alkaline
phosphatase activity and pyrophosphate production13.
These data suggest that elevated Tgase activity is an
additional feature defining the ‘hypertrophic phenotype’ in
articular chondrocytes, and underscore the similarities be-
tween the aging chondrocytes responsible for pathologic
Fig. 5. RT-PCR of type II Tgase and FXIIIA mRNA. Chondrocytes were incubated with no additives (control), 100 nM T3 or 750 nM T4 for
4 h. Total RNA was extracted and RT-PCR was performed using primer sequences that recognize human type II Tgase, FXIIIA or the
housekeeping gene GAPDH. Results are expressed as a densitometric ratio of (A) type II Tgase mRNA to GAPDH mRNA and (B) FXIIIA
mRNA to GAPDH mRNA. There were no significant differences in quantities of type II Tgase or FXIIIA mRNA between control cultures and
those treated with thyroid hormones.
Fig. 6. Detection of type II Tgase by Western blotting. Chondro-
cytes were incubated with no additives or 100–750 nM T4 for 4 h.
Lysed whole cell layer samples, corrected for protein content, were
run on 10% Bis-Tris gels. After transfer to PVDF membranes,
immunoreactive type II Tgase (85 kDa) was detected with an
anti-type II Tgase antibody (Upstate Biotechnology, Lake Placid,
NY), a peroxidase-linked secondary antibody and Supersignal®.
Moderate increases were noted in type II Tgase protein levels in
the presence of T4.
Fig. 7. Detection of FXIIIA by Western blotting. Chondrocytes were
incubated with no additives or 100–750 nM T4 for 4 h. Lysed whole
cell layer samples, corrected for protein content, were run on 10%
Bis-Tris gels. After transfer to PVDF membranes, immunoreactive
FXIIIA (85 kDa) was detected with an anti-FXIIIA antibody (Calbio-
chem), a peroxidase-linked secondary antibody and Supersignal®.
Moderate increases were noted in FXIIIA protein levels in the
presence of thyroid hormones.
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mineralization in articular cartilage and ‘true’ hypertrophic
growth plate chondrocytes.
Although Tgase may play an important role in the matrix
changes associated with degenerative arthritis2,5, little is
known about the regulation of the Tgase enzymes in
articular cartilage. In other tissues, proteases, such as
thrombin and trypsin, stimulate Tgase activity7,8. We show
in this study that thyroid hormones increase endoprotein-
ase activity. These proteases then may directly stimulate
Tgase activity through a variety of mechanisms, including
direct activation of the pro-Tgase form of FXIIIA24,25. Thy-
roid hormones also increase the percentage of Tgase
activity in the matrix. It is the extracellular enzyme that likely
participates in the matrix changes that facilitate pathologic
matrix mineralization in degenerative arthritis.
The classic effects of thyroid hormones are mediated
through nuclear receptors for T3, which on ligand binding,
act directly on gene transcription. However, thyroid hor-
mones also have well-described non-genomic effects.
These are rapid effects that occur at the plasma membrane
or in the cytosol and include effects on Na/H antiport26 and
adenylate cyclase activity22. The effects of thyroid hormone
on Tgase activity in chondrocytes occur as early as 15 min
after exposure. They are at least partially dependent on
protein synthesis, but do not require new mRNA synthesis
or conversion of T4 to T3. Altogether, these data support
the hypothesis that stimulation of Tgase activity may be an
additional non-genomic effect of thyroid hormone. The
effect of thyroid hormone on Na/H antiport involves
Fig. 8. Quantification of FXIIIA by ELISA. FXIIIA levels were
measured by ELISA in the whole cell layer of chondrocytes
incubated with or without T4 for 4 h. Results are expressed as
means±standard errors of the mean (N8). Small insignificant
increases in FXIIIA levels were detectable by ELISA (P>0.05).
Fig. 9. The effect of protein kinase C inhibitors on the ability of T4
to stimulate Tgase activity. Chondrocytes were incubated with no
additives (control), or with 750 nM T4 with and without the protein
kinase C inhibitor, 10 nM NGIC, for 4 h. Tgase activity was
measured in the whole cell layer. Results are expressed as
means±standard errors of the mean (N8). NGIC alone slightly
increased Tgase activity (P<0.04). NGIC suppressed the ability of
T4 to stimulate Tgase activity (P<0.01).
Fig. 10. The effect of T4 on cAMP levels in chondrocytes. Chondro-
cytes were incubated with no additives (control), or with 750 nM T4
with or without 25 µM forskolin (FS) and 500 µM IBMX. After 4 h,
cAMP levels and Tgase activity were measured in the whole cell
layer. Solid bars represent cAMP levels, while hatched bars
represent Tgase activity levels. Results are expressed as
means±standard errors of the mean (N6). There were no differ-
ences in cAMP levels in the presence of T4 (P>0.01).
Table III
The effect of T4 on endoproteinase secretion by chondrocytes
Endoproteinase activity (ng)*
Cell layer Media
Control 0 (none detected) 0 (none detected)
T4 96±3 239±13
*Chondrocytes were incubated with no additives (control) or with
750 nM T4 for 4 h. The endoproteinase activity in the cell layer and
media was measured using the SpecWorks™ Protease Assay Kit
(Novagen). Results are expressed as nanogram equivalents of a
standard endoproteinase (Alcalase®), and are shown as
means±standard deviations (N3).
Fig. 11. The effect of the protease inhibitor α1 antitrypsin (a1AT) on
T4-induced Tgase levels. Chondrocytes were incubated with and
without 750 nM T4 for 4 h in the presence or absence of 50 µg/ml
α1 antitrypsin. Tgase activity was measured in the cell layer and
corrected for protein. Results are expressed as means±
standard errors of the mean (N6). α1 antitrypsin significantly
suppressed T4-induced Tgase activity (P<0.02).
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signaling through protein kinase C, and our work supports a
similar protein kinase C-dependence.
The concentrations of thyroid hormones necessary to
affect Tgase levels in articular chondrocytes are twofold
higher than those measured in the circulation27, and are
slightly higher than those employed in other studies. There
may be a different dose response for mature articular
chondrocytes compared with younger chondrocytes or
for non-genomic rather than nuclear-receptor mediated
effects. We are not suggesting that T4 necessarily regu-
lates Tgase activity in articular cartilage in vivo. There is no
epidemiologic evidence that associates degenerative
arthritis or calcium crystal deposition with hyperthyroid
states. Conversely, remarkably little is known about local
thyroid hormone metabolism in the joint. We demon-
strate the presence of the type II deiodinase on articular
chondrocytes, and show rapid conversion of T4 to T3 by
chondrocytes. Serine proteases, such as elastase, which
are present in synovial fluids in settings of inflammation
and injury, cleave thyroid-binding globulins and dra-
matically increase local levels of free T428. As T4 exposure
also increases activity of endogenous proteinases,
this may further increase local levels of thyroid hormone.
Thyroid hormones have been shown to upregulate pro-
teinase genes in other settings, such as during tadpole
development29.
In summary, we have shown in this study that thyroid
hormones increase Tgase activity in adult articular
chondrocytes through a probable non-genomic mechanism
that is at least partially dependent on protein kinase C
activity and involves an increase in the activity of endog-
enous endoproteinases. These findings support the
hypothesis that Tgase is an additional component of the
‘hypertrophic phenotype’, and that factors that induce this
phenotype likely contribute to pathologic mineralization in
aging articular cartilage.
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